WO2010018563A3 - Compositions et procédés de pronostic d'un lymphome - Google Patents

Compositions et procédés de pronostic d'un lymphome Download PDF

Info

Publication number
WO2010018563A3
WO2010018563A3 PCT/IL2009/000764 IL2009000764W WO2010018563A3 WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3 IL 2009000764 W IL2009000764 W IL 2009000764W WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
compositions
lymphoma
methods
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2009/000764
Other languages
English (en)
Other versions
WO2010018563A2 (fr
Inventor
Moshe Hoshen
Gila Lithwick Yanai
Meir Lahav
Ranit Aharonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Rosetta Genomics Ltd
Original Assignee
Mor Research Applications Ltd
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd, Rosetta Genomics Ltd filed Critical Mor Research Applications Ltd
Publication of WO2010018563A2 publication Critical patent/WO2010018563A2/fr
Publication of WO2010018563A3 publication Critical patent/WO2010018563A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des compositions et des procédés de pronostic d'un lymphome malin. Les compositions sont des molécules de micro-ARN associées au pronostic d'un lymphome, ainsi que diverses molécules d'acide nucléique liées à celles-ci ou dérivées de celles-ci.
PCT/IL2009/000764 2008-08-12 2009-08-05 Compositions et procédés de pronostic d'un lymphome Ceased WO2010018563A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8801508P 2008-08-12 2008-08-12
US61/088,015 2008-08-12

Publications (2)

Publication Number Publication Date
WO2010018563A2 WO2010018563A2 (fr) 2010-02-18
WO2010018563A3 true WO2010018563A3 (fr) 2010-04-15

Family

ID=41259376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000764 Ceased WO2010018563A2 (fr) 2008-08-12 2009-08-05 Compositions et procédés de pronostic d'un lymphome

Country Status (1)

Country Link
WO (1) WO2010018563A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093924A1 (fr) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Molécules d'acide nucléique modifiées et leurs utilisations
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2016077125A1 (fr) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Molécules d'acide nucléique de remplacement contenant une quantité réduite d'uracile et utilisations associées
EP3405579A1 (fr) 2016-01-22 2018-11-28 Modernatx, Inc. Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
SI3458083T1 (sl) 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
WO2017218704A1 (fr) 2016-06-14 2017-12-21 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP4484443A3 (fr) 2016-06-29 2025-03-26 CRISPR Therapeutics AG Matériaux et méthodes de traitement de l'ataxie de friedreich et d'autres troubles associés
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
JP7305534B2 (ja) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
CN110402145A (zh) 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
EP3585807A1 (fr) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Matériaux et procédés pour le traitement de la maladie de parkinson à début précoce (park1) et d'autres états pathologiques ou troubles associés au gène alpha (snca)
EP3585895A1 (fr) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Compositions et méthodes pour l'édition génétique
WO2018154459A1 (fr) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Matériaux et procédés pour le traitement de l'hyperoxalurie primitive de type 1 (ph1) et d'autres états ou troubles associés au gène de l'alanine glyoxylate aminotransférase (agxt)
EP3585898A1 (fr) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Matériaux et procédés pour le traitement de l'ataxie spinocérébelleuse de type 1 (sca1) et d'autres états ou troubles liés au gène de l'ataxie spinocérébelleuse de type 1 (atxn1)
EP3585900B1 (fr) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Matériels et méthodes de traitement d'ataxia spinocerebellaire de type 2 (sca2) et d'autres maladies ou de troubles liés au gene du protéine ataxia spinocerebellaire de type 2 (sca2)
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3675817A1 (fr) 2017-08-31 2020-07-08 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
CA3082450A1 (fr) 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materiaux et methodes pour le traitement de la retinite pigmentaire autosomique dominante
WO2019123430A1 (fr) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Substances et méthodes pour le traitement du syndrome d'usher de type 2a et/ou de la rétinite pigmentaire autosomique récessive (arrp) non syndromique
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
EP3773745A1 (fr) 2018-04-11 2021-02-17 ModernaTX, Inc. Arn messager comprenant des éléments d'arn fonctionnels
WO2019241315A1 (fr) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
WO2020061457A1 (fr) 2018-09-20 2020-03-26 Modernatx, Inc. Préparation de nanoparticules lipidiques et leurs méthodes d'administration
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN118697900A (zh) 2019-01-31 2024-09-27 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
EP3987027A1 (fr) 2019-06-24 2022-04-27 ModernaTX, Inc. Arn messager résistant à l'endonucléase et utilisations correspondantes
WO2021046451A1 (fr) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation de protéine accordable dhfr
CN112941176A (zh) * 2019-12-10 2021-06-11 复旦大学 肿瘤乳酸微环境相关非编码小rna分子谱及其应用
CA3169669A1 (fr) 2020-01-31 2021-08-05 Modernatx, Inc. Procedes de preparation de nanoparticules lipidiques
EP4185274A1 (fr) 2020-07-24 2023-05-31 Strand Therapeutics Inc. Nanoparticule de nanoparticule lipidique comprenant des nucléotides modifiés
EP4192432A1 (fr) 2020-08-06 2023-06-14 ModernaTX, Inc. Procédés de préparation de nanoparticules lipidiques
AR124599A1 (es) 2021-01-08 2023-04-12 Strand Therapeutics Inc Constructos de expresión y usos de estos
EP4334446A1 (fr) 2021-05-03 2024-03-13 CureVac SE Séquence d'acide nucléique améliorée pour l'expression spécifique de type cellulaire
WO2023166425A1 (fr) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Procédés et compositions pour le traitement d'affections liées à la protéine 3 de type angiopoïétine (angptl3)
CN119317430A (zh) 2022-04-26 2025-01-14 斯特兰德生物科技公司 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途
US20250375389A1 (en) 2022-07-29 2025-12-11 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026482A1 (fr) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions de nanoparticules lipidiques comprenant des dérivés lipidiques de surface et utilisations associées
WO2024026475A1 (fr) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions pour administration à des cellules souches et progénitrices hématopoïétiques (hspc) et utilisations associées
KR20260006623A (ko) 2023-04-28 2026-01-13 센젠 센신 바이오테크놀로지 컴퍼니 리미티드 변형된 전달 담체 및 이의 용도
WO2024259373A1 (fr) 2023-06-14 2024-12-19 Modernatx, Inc. Composés et compositions pour administration d'agents thérapeutiques
WO2025160381A1 (fr) 2024-01-26 2025-07-31 Modernatx, Inc. Procédés de préparation de nanoparticules lipidiques
WO2025166202A1 (fr) 2024-01-31 2025-08-07 Modernatx, Inc. Compositions de nanoparticules lipidiques comprenant des dérivés d'acide sialique et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
EP1676914A1 (fr) * 2003-09-22 2006-07-05 Aichi Prefecture Type de lymphome pathologique et procede d'evaluation de diagnostic
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (fr) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Acides nucléiques apparentés au cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676914A1 (fr) * 2003-09-22 2006-07-05 Aichi Prefecture Type de lymphome pathologique et procede d'evaluation de diagnostic
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (fr) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Acides nucléiques apparentés au cancer

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 841A, ISSN: 0006-4971 *
BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 1049A, ISSN: 0006-4971 *
CALIN G A ET AL: "A MICRORNA SIGNATURE ASSOCIATED WITH PROGNOSIS AND PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 *
CALIN GEORGE A ET AL: "MicroRNA signatures in human cancers", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 6, no. 11, 1 November 2006 (2006-11-01), pages 857 - 866, XP002473506, ISSN: 1474-175X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), LAWRIE CHARLES H ET AL: "MicroRNA expression profiling of diffuse large B-cell lymphoma reveals differences between germinal center-like and activated B cell-like subtypes.", XP002554909, Database accession no. PREV200600185370 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2007 (2007-11-01), ROBERTUS JAN-LUKAS ET AL: "Differences in the C13orf25 miRNA cluster in non-Hodgkin lymphoma and normal B-Cell subtypes", XP002554910, Database accession no. PREV200800218858 *
EIS P S ET AL: "Accumulation of miR-155 and BIC RNA in human B cell lymphomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 102, no. 10, 1 March 2005 (2005-03-01), pages 3627 - 3632, XP002396794, ISSN: 0027-8424 *
HE LIN ET AL: "A microRNA polycistron as a potential human oncogene", NATURE (LONDON), vol. 435, no. 7043, June 2005 (2005-06-01), pages 828 - 833, XP002554907, ISSN: 0028-0836 *
LAWRIE CHARLES H ET AL: "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", BRITISH JOURNAL OF HAEMATOLOGY,, vol. 141, no. 5, 3 March 2008 (2008-03-03), pages 672 - 675, XP002545705 *
LAWRIE CHARLES H ET AL: "MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 5, September 2007 (2007-09-01), pages 1156 - 1161, XP002554905, ISSN: 0020-7136 *
OTA A ET AL: "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 9, 1 May 2004 (2004-05-01), pages 3087 - 3095, XP002996247, ISSN: 0008-5472 *
ROEHLE ANJA ET AL: "MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.", BRITISH JOURNAL OF HAEMATOLOGY SEP 2008, vol. 142, no. 5, 5 June 2008 (2008-06-05), pages 732 - 744, XP002554906, ISSN: 1365-2141 *
TAGAWA HIROYUKI ET AL: "Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development", CANCER SCIENCE, vol. 98, no. 9, September 2007 (2007-09-01), pages 1482 - 1490, XP002554908, ISSN: 1347-9032 *
TANZER A ET AL: "Molecular Evolution of a MicroRNA Cluster", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 339, no. 2, 28 May 2004 (2004-05-28), pages 327 - 335, XP004506520, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2010018563A2 (fr) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
WO2009108866A3 (fr) Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
WO2009108217A3 (fr) Compositions comprenant un arnsi de k-ras et procédés d’utilisation
WO2009108860A3 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2009061381A3 (fr) Variants d'alpha-amylase à propriétés modifiées
WO2009153775A3 (fr) Procédés permettant de différencier différents types de cancers du poumon
WO2007139723A8 (fr) Amorces d'oligonucléotides chimiquement modifiées pour l'amplification de l'acide nucléique
WO2007148235A3 (fr) Acides nucléiques apparentés au cancer
WO2010127304A3 (fr) Procédés de séquençage
WO2010048585A3 (fr) Composés oligomères et méthodes
WO2009039189A3 (fr) Compositions comprenant des arnsi de stat3 et leurs procédés d'utilisation
WO2008069906A3 (fr) Expression numérisée de l'analyse génétique
WO2009012263A3 (fr) Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn
WO2009108918A3 (fr) Procédés et systèmes pour un réseautage social fondé sur des séquences d’acides nucléiques
WO2011156654A3 (fr) Caractérisation de voies de cellules
WO2008152131A3 (fr) Inhibition par arni de l'expression du canal alpha-enac
WO2010045384A3 (fr) Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes
WO2011160052A3 (fr) Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence
WO2009153774A3 (fr) Compositions et procédés pour le pronostic du cancer des ovaires
WO2009120712A3 (fr) Compositions et procédés pour diagnostiquer et traiter un mélanome
WO2009135219A3 (fr) Détection d'une prédisposition génétique à des états associés à l'ostéoarthrite
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2